OPKO Health, Inc. is growing its business portfolio to address critical health needs with its OPKO Pharmaceuticals division. Rayaldee treats stage 3 or 4 chronic kidney disease (CKD) with secondary hyperparathyroidism (SHPT) and Vitamin D insufficiency. At OPKO Health, the entrepreneurial acumen of our founder and CEO, Dr. Phillip Frost, has led to the development of a diverse healthcare company flexible enough to adapt to evolving patient needs....
